Sage Therapeutics, Inc.
SAGE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -52.3% | 1,024.8% | 21.8% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 77.1% | 97.5% | 89.4% | 91.2% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $1 | $1 | $0 |
| Operating Income | -$0 | -$1 | -$1 | -$0 |
| % Margin | -1,048.3% | -670.7% | -7,116.7% | -7,306.7% |
| Other Income/Exp. Net | $0 | $0 | $0 | $0 |
| Pre-Tax Income | -$0 | -$1 | -$1 | -$0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$0 | -$1 | -$1 | -$0 |
| % Margin | -971.5% | -626.3% | -6,547.8% | -7,146.9% |
| EPS | -6.59 | -9.05 | -8.49 | -7.68 |
| % Growth | 27.2% | -6.6% | -10.5% | – |
| EPS Diluted | -6.59 | -9.05 | -8.49 | -7.68 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$1 | -$1 | -$0 |
| % Margin | -992.9% | -630.5% | -7,102.1% | -7,240.4% |